Regulatory and Safety Aspects of Cell and Gene Therapy
Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use.
Gene therapy is a technique that modifies a person’s genes to treat or cure disease. Gene therapies can work by several mechanisms:
- Replacing a disease-causing gene with a healthy copy of the gene
- Inactivating a disease-causing gene that is not functioning properly
- Introducing a new or modified gene into the body to help treat a disease
Gene therapy products are being studied to treat diseases including cancer, genetic diseases, and infectious diseases.
There are a variety of types of gene therapy products, including:
- Plasmid DNA: Circular DNA molecules can be genetically engineered to carry therapeutic genes into human cells.
- Viral vectors: Viruses have a natural ability to deliver genetic material into cells, and therefore some gene therapy products are derived from viruses. Once viruses have been modified to remove their ability to cause infectious disease, these modified viruses can be used as vectors (vehicles) to carry therapeutic genes into human cells.
- Bacterial vectors: Bacteria can be modified to prevent them from causing infectious disease and then used as vectors (vehicles) to carry therapeutic genes into human tissues.
- Human gene editing technology: The goals of gene editing are to disrupt harmful genes or to repair mutated genes.
- Patient-derived cellular gene therapy products: Cells are removed from the patient, genetically modified (often using a viral vector) and then returned to the patient.
Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy
November 16-17, 2026
19th International Conference on Human Genomics and Genomic Medicine
Tokyo, Japan
February 18-19, 2027
22nd World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
Singapore City, Singapore
March 11-12, 2027
17th International Conference on Human Genetics and Genetic Diseases
Berlin, Germany
Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers
Recommended Sessions
- Cancer Genetics
- Animal Genetics
- Bioinformatics
- Biomarkers
- Cytogenetics
- Epigenetics & Chromatin
- Forensic Genetics
- Genetic Disorders
- Genetics
- Genome Integrity
- Human Genetics
- Molecular and Cellular Genetics
- Molecular biology
- Neurogenetics
- Nutrigenetics
- Pediatric Geneticist
- Plant Genetics And Molecular Pharming
- Regulatory and Safety Aspects of Cell and Gene Therapy
- Reproductive Genetics/Prenatal Genetics
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Advanced Imaging and Single-Cell Technologies - cellscience-cs-2027 (UK)
- Animal Genetics - Genome 2027 (Germany)
- Artificial Intelligence in Cell and Molecular Research - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - cellscience-cs-2027 (UK)
- Bioinformatics and Computational Biology - Genome 2027 (Germany)
- Biomarkers and Microarrays - Genome 2027 (Germany)
- Biotechnology and Molecular Therapeutics - cellscience-cs-2027 (UK)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Cell Biology and Molecular Oncology - cellscience-cs-2027 (UK)
- Cancer Genomics - Genome 2027 (Germany)
- Cell Biology and Cellular Mechanisms - cellscience-cs-2027 (UK)
- Cellular Metabolism and Metabolic Biology - cellscience-cs-2027 (UK)
- Cellular signaling and Signal Transduction - cellscience-cs-2027 (UK)
- Clinical genomics - Genome 2027 (Germany)
- Comparative Genomics - Genome 2027 (Germany)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Emerging Technologies and Future Directions in Cell Science - cellscience-cs-2027 (UK)
- Epigenomics and Epigenetics - Genome 2027 (Germany)
- Functional Genomics - Genome 2027 (Germany)
- Gene Editing and Genetic Engineering - Genome 2027 (Germany)
- Genetic Disorder - Genome 2027 (Germany)
- Genetics, Genomics and Genome Biology - cellscience-cs-2027 (UK)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Genomic Instability - Genome 2027 (Germany)
- Genomic Medicine - Genome 2027 (Germany)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Immunology and Cellular Immunity - cellscience-cs-2027 (UK)
- Microbial Genomics - Genome 2027 (Germany)
- Molecular Biology and Gene Regulation - cellscience-cs-2027 (UK)
- Molecular Diagnostics and Biomarkers - cellscience-cs-2027 (UK)
- Molecular Medicine and Translational Research - cellscience-cs-2027 (UK)
- Molecular Microbiology and Host–Pathogen Interactions - cellscience-cs-2027 (UK)
- Next generation sequencing - Genome 2027 (Germany)
- Nutrigenomics - Genome 2027 (Germany)
- Personalized and Regenerative Medicine - Genome 2027 (Germany)
- Pharmacogenomics - Genome 2027 (Germany)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Plant Genomics and Molecular Pharming - Genome 2027 (Germany)
- Stem Cell Biology and Regenerative Medicine - cellscience-cs-2027 (UK)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Structural Genomics - Genome 2027 (Germany)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)
- Trends in Genomics and Pharmacogenomics - Genome 2027 (Germany)

